Artificial intelligence tools secure tomorrow’s electric grid
Cory Stuart of ORNL applies his expertise as a systems engineer to ensure the secure and timely transfer of millions of measurements of Earth’s atmosphere, fueling science around the world.
Thirty-two Oak Ridge National Laboratory employees were named among teams recognized by former DOE Secretary Dan Brouillette with Secretary’s Honor Awards as he completed his term. Four teams received new awards that reflect DOE responses to the coronavirus pandemic.
Three technologies developed by ORNL researchers have won National Technology Transfer Awards from the Federal Laboratory Consortium. One of the awards went to a team that adapted melt-blowing capabilities at DOE’s Carbon Fiber Technology Facility to enable the production of filter material for N95 masks in the fight against COVID-19.
Energy storage startup SPARKZ Inc. has exclusively licensed a battery cycling technology from ORNL designed to enable the rapid production of lithium-ion batteries commonly used in portable electronic devices and electric vehicles.
Six scientists at the Department of Energy’s Oak Ridge National Laboratory were named Battelle Distinguished Inventors, in recognition of obtaining 14 or more patents during their careers at the lab.
Oak Ridge National Laboratory researchers have developed a new family of cathodes with the potential to replace the costly cobalt-based cathodes typically found in today’s lithium-ion batteries that power electric vehicles and consumer electronics.
Six ORNL scientists have been elected as fellows to the American Association for the Advancement of Science, or AAAS.
The annual Director's Awards recognized four individuals and teams including awards for leadership in quantum simulation development and application on high-performance computing platforms, and revolutionary advancements in the area of microbial
Paul J. Hanson, ORNL Corporate Fellow, has been elected to the 2020 Class of Fellows of the American Geophysical Union.
Experiments led by researchers at ORNL have determined that several hepatitis C drugs can inhibit the SARS-CoV-2 main protease, a crucial protein enzyme that enables the novel coronavirus to reproduce.